黄色ブドウ球菌BSI/SSIワクチン:米国の市場機会分析・予測

◆英語タイトル:MarketVIEW: Staphylococcus aureus BSI/SSI vaccines (USA) - Staphylococcus aureus vaccines: USA commercial analysis, USA market forecast and size
◆商品コード:VAZ2006013
◆発行会社(リサーチ会社):VacZine Analytics
◆発行日:2019年5月
◆ページ数:n/a
◆レポート言語:英語
◆レポート形式:Executive presentation (~195 slides .pdf) + 1 MS Excel
workbook (.xls)
◆納品方法:Eメール
◆調査対象地域:米国
◆販売価格オプション(消費税別)
Region PriceUSD10,995 ⇒換算¥1,143,480見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVacZine Analytics社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
VacZine Analytics社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Staphylococcus aureus is a Gram-positive toxin-forming bacterium that is a widespread human commensal and pathogen. Approximately 30-60% of the population is colonized either permanently or intermittently. S.aureus (SA) is responsible for a wide range of clinical syndromes ranging from high mortality blood stream infections (BSIs) to community-based skin and soft tissue infections such as skin abscesses (SSTIs). SA is a common cause of healthcare-associated infections (HAIs) such as pneumonia and surgical site infections (SSIs). An antibiotic resistant form of S.aureus (MRSA) has become a major problem both in and out of the hospital with an estimated ~88-90K infections occurring in the USA each year with substantial economic burden.
SA vaccines which prevent and/or reduce the impact of SA infections are greatly needed although it is becoming accepted that a universal vaccine to impact upon all infection types and reduce colonization is an optimistic goal. Development has been thwarted with numerous failures. Recently, Pfizer vaccines were developing SA4Ag, a multicomponent vaccine (reached Phase IIb, fast track designation) to address SA BSI and SSIs in surgical patients undergoing elective open posterior spinal fusion procedures.

This MarketVIEW product consists of a detailed Executive presentation (~195 .pdf slides) and comprehensive MS-Excel workbook (.xls) which forecast the potential commercial value of a S.aureus “healthcare-associated” vaccine to target BSIs and SSIs in US surgical and End-stage renal disease patients (ESRD) in the US to 2030. For surgery patients, there is a sophisticated uptake methodology whereby specific surgical procedures are assigned a priority level along with an assessment of US state (group of) HO-MRSA risk. Efforts have been made to account for complex overlapping datasets so that discrete numbers of procedures can be forecast as eligible vaccine populations. The analysis also provides a detailed review of latest S.aureus (MRSA) US epidemiology (EIP, NHSN) , prevention/legislative efforts (HHS Action Plan), vaccinology and current R&D approaches/activity. MarketVIEW: Staphylococcus aureus BSI/SSI vaccine (USA) lays a solid groundwork designed to initiate or challenge any internal client assessment of this exciting but challenging commercial opportunity.

MarketVIEW: Staphylococcus aureus BSI/SSI vaccine (USA) lays a firm groundwork designed to initiate or challenge any internal client assessment of this exciting but challenging commercial opportunity.

THIS PRODUCT IS A SUMMARY PRESENTATION (.pdf, 195 slides) + 1 MODEL (.xls, 55 worksheets)

To order please contact your region account manager, buy “on-line” or order direct at: orders@vaczine-analytics.com

【レポートの目次】

PRODUCT CONTENTS:
Published May 2019 (CAT No: VAMV002)
****This product is a summary presentation (.pdf), a forecast model (.xls)
Contents – Summary presentation (.pdf)2
Contents
Author’s notes
Executive summary
[SECTION 1] Staphylococcus aureus BSI/SSI vaccines: key commercial model outputs
[SECTION 2] Staphylococcus aureus: disease background and epidemiology (USA)
[SECTION 3] Staphylococcus aureus: disease epidemiology – analysis of EIP 2005-2016 dataset
[SECTION 4] Staphylococcus aureus: disease epidemiology – analysis of NHSN 2011-2017 dataset
[SECTION 5] Staphylococcus aureus: HAIs, current progress in prevention and control
[SECTION 6] Staphylococcus aureus: the need and potential role for a vaccine
[SECTION 7] Staphylococcus aureus: designing the ideal vaccine approach
[SECTION 8] Staphylococcus aureus: vaccine R&D pipeline
[SECTION 9] Staphylococcus aureus: modelling vaccine commercial potential (USA)
[Appendix I] Staphylococcus aureus: review of clinical syndromes
[Appendix II] Staphylococcus aureus: historical/back-up epidemiological data
About VacZine Analytics
Disclaimer
PAGES: ~195 slides fully referenced/sourced. Available in .pdf form
Contents – Vaccine demand model (MS Excel-based)
Worksheets = >60 interconnected



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[黄色ブドウ球菌BSI/SSIワクチン:米国の市場機会分析・予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆